

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



山東威高集團醫用高分子製品股份有限公司  
**Shandong Weigao Group Medical Polymer Company Limited** \*  
*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

(Stock Code: 1066)

## **PROPOSED APPOINTMENT AND RESIGNATION OF EXECUTIVE DIRECTORS**

The board of directors of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) is pleased to announce the following changes to the Board:

1. Mr. Wang Daoming (王道明) (“**Mr. Wang**”) has been appointed as an executive director of the Company subject to shareholders approval; and
2. Mr. Nishili (倪世利) (“**Mr. Ni**”) has tendered his resignation as an executive director of the Company with effect from 31 December 2023.

The appointment of Mr. Wang will be subject to the approval by the shareholders of the Company at the upcoming general meeting. A circular containing further details of the proposed appointment, together with the relevant notice of the meeting and a proxy form, will be despatched to the shareholders of the Company accordingly.

### **APPOINTMENT OF MR. WANG DAOMING**

The Board is pleased to announce that Mr. Wang Daoming (“**Mr. Wang**”) has been appointed as an executive director of the Company subject to the approval by the shareholders of the Company at the upcoming general meeting or any adjournment thereof.

\* *For identification purpose only*

Mr. Wang, aged 44, currently is a director of Shandong Weigao Puri Pharmaceutical Packaging Co., Ltd.\* (referred to as “**Weigao Puri**”). Mr. Wang joined the Company in July 2009 and has served as sales, sales manager, assistant to the general manager in the pharma packaging materials division of the Company until February 2016. He worked as the sales director for the pharma packaging materials division from March 2016 to December 2019, and served as the vice president of sales of Weigao Puri from January 2020 to December 2022. Since January 2023, he has been serving as the executive vice general manager of Weigao Puri. Prior to joining the Company, Mr. Wang had started his own business for more than ten years, being responsible for the sales promotion and independent operation for multiple brands in Weihai. Mr. Wang graduated from China University of Geosciences majoring in visual communication design, and he has been engaged in the pharma packaging industry for nearly 20 years. He has extensive experience in industry marketing and corporation operations.

As at the date of this announcement, Mr. Wang has been granted a total of 500,000 non-listed domestic incentive shares of the Company. Mr. Wang has not held any other directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years and does not have any relationship with any director or senior management of the Company or with any substantial or controlling shareholder of the Company. A service contract will be entered into between Mr. Wang and the Company for a term of three years commencing on the effective date of his appointment for his services to the Company subject to the approval of the shareholders of the Company at the upcoming general meeting or any adjournment thereof. The service contract may be terminated by either party by giving to other party not less than three month’s written notice without payment of compensation (other than statutory compensation). Mr. Wang will waive his director emolument pursuant to the service contract. As at the date of this announcement, other than the shares mentioned above, Mr. Wang does not have any shareholding in the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, as far as the Board aware, there are no other matters which need to be brought to the attention of the Shareholders regarding the appointment of Mr. Wang or any other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules. The Board would like to express its warmest welcome to Mr. Wang to join the board of directors of the Company.

## **RESIGNATION OF MR. NI SHILI**

Mr. Ni has tendered his resignation as an executive director of the Company with effect from 31 December 2023 due to his other work arrangement. Mr. Ni has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the Stock Exchange of Hong Kong Limited and the shareholders of the Company.

## UPCOMING GENERAL MEETING

The proposed appointment of Mr. Wang as an executive director is subject to the approval by the shareholders of the Company at the upcoming general meeting. A circular containing further details of the proposed appointment of directors together with the relevant notice of the meeting and a proxy form, will be despatched to the shareholders of the Company accordingly.

The Board is of the view that Mr. Wang has extensive experience in the industry and has been with the Group for a long period of time. He has demonstrated outstanding capability and is qualified to lead and drive further growth of the Group.

The Company would like to take this opportunity to express its sincere gratitude to Mr. Ni for his valuable contribution to the operation and development of the Group and the work of the Board during his directorship with the Company. He has been instrumental in the growth and in successfully cementing the leading position of the Group in the medical device industry.

By Order of the Board

**Shandong Weigao Group Medical Polymer Company Limited**

**Long Jing**

*Chairman*

29 December 2023

Weihai, Shandong, the PRC

*As at the date of this announcement, the Board Comprises:*

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive Director*)

Mr. Lu Junqiang (*Executive Director*)

Mr. Ni Shili (*Executive Director*)

Mr. Tang Zhengpeng (*Non-Executive Director*)

Mr. Chen Lin (*Non-Executive Director*)

Mr. Li Guohui (*Independent non-executive Director*)

Mrs. Meng Hong (*Independent non-executive Director*)

Mr. Li Qiang (*Independent non-executive Director*)